Citations (65)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (10)
Sarah Ann Smith, Gia Han Le, Kayla M. Teopiz, Angela T.H. Kwan, Taeho Greg Rhee, Roger C. Ho, Jie Wu, Bing Cao, Felicia Ceban & Roger S. McIntyre. (2024) Effects of cannabidiol and Δ9-tetrahydrocannabinol on cytochrome P450 enzymes: a systematic review. Drug Metabolism Reviews 56:2, pages 164-174.
Read now
Read now
Uma Anand, Christian Oldfield, Barbara Pacchetti, Praveen Anand & Mikael H Sodergren. (2021) Dose-Related Inhibition of Capsaicin Responses by Cannabinoids CBG, CBD, THC and their Combination in Cultured Sensory Neurons. Journal of Pain Research 14, pages 3603-3614.
Read now
Read now
Richard J. Schrot & John R. Hubbard. (2016) Cannabinoids: Medical implications. Annals of Medicine 48:3, pages 128-141.
Read now
Read now
Philip Robson. (2011) Abuse potential and psychoactive effects of δ-9-tetrahydrocannabinol and cannabidiol oromucosal spray (Sativex), a new cannabinoid medicine. Expert Opinion on Drug Safety 10:5, pages 675-685.
Read now
Read now
Radu Tanasescu, David Rog & Cris S Constantinescu. (2011) A drug discovery case history of ‘delta-9-tetrahydrocannabinol, cannabidiol’. Expert Opinion on Drug Discovery 6:4, pages 437-452.
Read now
Read now
Ethan B Russo. (2008) Cannabinoids in the management of difficult to treat pain. Therapeutics and Clinical Risk Management 4:1, pages 245-259.
Read now
Read now
Frances R. Levin & Herbert D. Kleber. (2008) Use of Dronabinol for Cannabis Dependence: Two Case Reports and Review. American Journal on Addictions 17:2, pages 161-164.
Read now
Read now
Bill H. McCarberg. (2007) Cannabinoids. Journal of Pain & Palliative Care Pharmacotherapy 21:3, pages 19-28.
Read now
Read now
Franjo Grotenhermen. (2004) Clinical Pharmacodynamics of Cannabinoids. Journal of Cannabis Therapeutics 4:1, pages 29-78.
Read now
Read now
Kirsten R Müller-Vahl. (2003) Cannabinoids reduce symptoms of Tourette’s syndrome. Expert Opinion on Pharmacotherapy 4:10, pages 1717-1725.
Read now
Read now
Articles from other publishers (55)
William Brennan, Alex R. KelmanAlexander B. Belser. (2023) A Systematic Review of Reporting Practices in Psychedelic Clinical Trials: Psychological Support, Therapy, and Psychosocial Interventions. Psychedelic Medicine 1:4, pages 218-229.
Crossref
Crossref
Yuting Wen, Zefeng Wang, Rui Zhang, Yuying Zhu, Guoqiang Lin, Ruixiang Li & Jiange Zhang. (2023) The antinociceptive activity and mechanism of action of cannabigerol. Biomedicine & Pharmacotherapy 158, pages 114163.
Crossref
Crossref
Joao P. De Aquino, Anees Bahji, Oscar Gómez & Mehmet Sofuoglu. (2022) Alleviation of opioid withdrawal by cannabis and delta-9-tetrahydrocannabinol: A systematic review of observational and experimental human studies. Drug and Alcohol Dependence 241, pages 109702.
Crossref
Crossref
Jeremy D. Henson, Luis Vitetta & Sean Hall. (2022) Tetrahydrocannabinol and cannabidiol medicines for chronic pain and mental health conditions. Inflammopharmacology 30:4, pages 1167-1178.
Crossref
Crossref
Christiana J. Smith, Daniela Vergara, Brian Keegan & Nick Jikomes. (2022) The phytochemical diversity of commercial Cannabis in the United States. PLOS ONE 17:5, pages e0267498.
Crossref
Crossref
Sara Jane Ward, Aron H Lichtman, Daniele Piomelli & Linda A Parker. (2021) Cannabinoids and Cancer Chemotherapy-Associated Adverse Effects. JNCI Monographs 2021:58, pages 78-85.
Crossref
Crossref
Neda Tadayon & Ali Ramazani. (2021) A review on the syntheses of Dronabinol and Epidiolex as classical cannabinoids with various biological activities including those against SARS-COV2. Journal of the Iranian Chemical Society 18:10, pages 2517-2534.
Crossref
Crossref
Anne K Schlag, Chandni Hindocha, Rayyan Zafar, David J Nutt & H Valerie Curran. (2021) Cannabis based medicines and cannabis dependence: A critical review of issues and evidence. Journal of Psychopharmacology 35:7, pages 773-785.
Crossref
Crossref
Dennis J. Sholler, Marilyn A. Huestis, Benjamin Amendolara, Ryan Vandrey & Ziva D. Cooper. (2020) Therapeutic potential and safety considerations for the clinical use of synthetic cannabinoids. Pharmacology Biochemistry and Behavior 199, pages 173059.
Crossref
Crossref
Matthew Chung & Salahadin Abdi. 2020. Cannabis in Medicine. Cannabis in Medicine
325
343
.
Beniamino Palmieri, Carmen Laurino & Maria Vadalà. (2019) Spontaneous, anecdotal, retrospective, open-label study on the efficacy, safety and tolerability of cannabis galenical preparation (Bedrocan). International Journal of Pharmacy Practice 27:3, pages 264-270.
Crossref
Crossref
. (2019) A Clinical Case Study of a 45 y/o Female Suffering with PTSD, Bipolar D/O, Depression, Anxiety and Chronic Pain Syndrome Taking 42-58 Pills Per Day and Weaned off of All Medications Using Medical Cannabis. Journal of Clinical Review & Case Reports 4:1.
Crossref
Crossref
Brishna S. Kamal, Fatima Kamal & Daniel E. Lantela. (2018) Cannabis and the Anxiety of Fragmentation—A Systems Approach for Finding an Anxiolytic Cannabis Chemotype. Frontiers in Neuroscience 12.
Crossref
Crossref
Wajd Alkabbani, Ruth Ann Marrie, Shawn Bugden, Silvia Alessi-Severini, Paul Daeninck, James Bolton, Jitender Sareen & Christine Leong. (2018) Pharmaceutical cannabinoid use in Manitoba, 2004/05 to 2014/15: a population-based cross-sectional study. CMAJ Open 6:4, pages E637-E642.
Crossref
Crossref
Barbara Scolnick. (2018) Treatment of anorexia nervosa with palmitoylethanoamide. Medical Hypotheses 116, pages 54-60.
Crossref
Crossref
Ethan B. Russo & Jahan Marcu. 2017. Cannabinoid Pharmacology. Cannabinoid Pharmacology
67
134
.
Ethan B. Russo. (2016) Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other Treatment-Resistant Syndromes. Cannabis and Cannabinoid Research 1:1, pages 154-165.
Crossref
Crossref
Ethan B. Russo. (2016) Current Therapeutic Cannabis Controversies and Clinical Trial Design Issues. Frontiers in Pharmacology 7.
Crossref
Crossref
Michelle R. Lofwall, Shanna Babalonis, Paul A. Nuzzo, Samy Claude Elayi & Sharon L. Walsh. (2016) Opioid withdrawal suppression efficacy of oral dronabinol in opioid dependent humans. Drug and Alcohol Dependence 164, pages 143-150.
Crossref
Crossref
Joshua A. Lile, Michael J. Wesley, Thomas H. Kelly & Lon R. Hays. (2016) Separate and combined effects of gabapentin and [INCREMENT]9-tetrahydrocannabinol in humans discriminating [INCREMENT]9-tetrahydrocannabinol. Behavioural Pharmacology 27:2 and 3 - Special Issue, pages 215-224.
Crossref
Crossref
Jenny L. Wiley, R. Allen Owens & Aron H. Lichtman. 2018. The Behavioral Neuroscience of Drug Discrimination. The Behavioral Neuroscience of Drug Discrimination
153
173
.
William G. Notcutt. (2015) Clinical Use of Cannabinoids for Symptom Control in Multiple Sclerosis. Neurotherapeutics 12:4, pages 769-777.
Crossref
Crossref
Leslie H. Lundahl & Mark K. Greenwald. (2015) Effect of oral THC pretreatment on marijuana cue-induced responses in cannabis dependent volunteers. Drug and Alcohol Dependence 149, pages 187-193.
Crossref
Crossref
Jason M. Wiebelhaus, Travis W. Grim, Robert A. Owens, Matthew F. Lazenka, Laura J. Sim-Selley, Rehab A. Abdullah, Micah J. Niphakis, Robert E. Vann, Benjamin F. Cravatt, Jenny L. Wiley, S. Stevens Negus & Aron H. Lichtman. (2015)
Δ
9
-Tetrahydrocannabinol and Endocannabinoid Degradative Enzyme Inhibitors Attenuate Intracranial Self-Stimulation in Mice
. Journal of Pharmacology and Experimental Therapeutics 352:2, pages 195-207.
Crossref
Crossref
Dana Turcotte, Malcolm Doupe, Mahmoud Torabi, Andrew Gomori, Karen Ethans, Farid Esfahani, Katie Galloway & Mike Namaka. (2015) Nabilone as an Adjunctive to Gabapentin for Multiple Sclerosis-Induced Neuropathic Pain: A Randomized Controlled Trial. Pain Medicine 16:1, pages 149-159.
Crossref
Crossref
Ethan B. Russo & Andrea G. Hohmann. 2015. Treatment of Chronic Pain by Medical Approaches. Treatment of Chronic Pain by Medical Approaches
179
195
.
Mohammed A. Issa, Sanjeet Narang, Robert N. Jamison, Edward Michna, Robert R. Edwards, David M. Penetar & Ajay D. Wasan. (2014) The Subjective Psychoactive Effects of Oral Dronabinol Studied in a Randomized, Controlled Crossover Clinical Trial for Pain. The Clinical Journal of Pain 30:6, pages 472-478.
Crossref
Crossref
Jingchun Sun, Liang-Chin Huang, Hua Xu & Zhongming Zhao. (2014) Network-Assisted Prediction of Potential Drugs for Addiction. BioMed Research International 2014, pages 1-9.
Crossref
Crossref
Ethan B. Russo & Andrea G. Hohmann. 2013. Comprehensive Treatment of Chronic Pain by Medical, Interventional, and Integrative Approaches. Comprehensive Treatment of Chronic Pain by Medical, Interventional, and Integrative Approaches
181
197
.
Peter A. Ste‐Marie, Mary‐Ann Fitzcharles, Ann Gamsa, Mark A. Ware & Yoram Shir. (2012) Association of herbal cannabis use with negative psychosocial parameters in patients with fibromyalgia. Arthritis Care & Research 64:8, pages 1202-1208.
Crossref
Crossref
Stephen D. Roughley, Helen Browne, Alba T. Macias, Karen Benwell, Teresa Brooks, Jalanie D’Alessandro, Zoe Daniels, Sarah Dugdale, Geraint Francis, Ben Gibbons, Terance Hart, Timothy Haymes, Guy Kennett, Sean Lightowler, Natalia Matassova, Howard Mansell, Angela Merrett, Anil Misra, Anthony Padfield, Rachel Parsons, Robert Pratt, Alan Robertson, Heather Simmonite, Kiri Tan, Steven B. Walls & Melanie Wong. (2012) Fatty acid amide hydrolase inhibitors. 3: Tetra-substituted azetidine ureas with in vivo activity. Bioorganic & Medicinal Chemistry Letters 22:2, pages 901-906.
Crossref
Crossref
Jon E. Grant, Brian L. Odlaug, Samuel R. Chamberlain & Suck Won Kim. (2011) Dronabinol, a cannabinoid agonist, reduces hair pulling in trichotillomania: a pilot study. Psychopharmacology 218:3, pages 493-502.
Crossref
Crossref
Frances R. Levin, John J. Mariani, Daniel J. Brooks, Martina Pavlicova, Wendy Cheng & Edward V. Nunes. (2011) Dronabinol for the treatment of cannabis dependence: A randomized, double-blind, placebo-controlled trial. Drug and Alcohol Dependence 116:1-3, pages 142-150.
Crossref
Crossref
Samya Nasr & Darcie Streetman. 2011. Diet and Nutrition in Palliative Care. Diet and Nutrition in Palliative Care
417
426
.
Kerri Alexandra Schoedel, Nancy Chen, Annie Hilliard, Linda White, Colin Stott, Ethan Russo, Stephen Wright, Geoffrey Guy, Myroslava K. Romach & Edward M. Sellers. (2011) A randomized, double‐blind, placebo‐controlled, crossover study to evaluate the subjective abuse potential and cognitive effects of nabiximols oromucosal spray in subjects with a history of recreational cannabis use. Human Psychopharmacology: Clinical and Experimental 26:3, pages 224-236.
Crossref
Crossref
Mark A. Ware & Emmanuelle St Arnaud‐Trempe. (2010) The abuse potential of the synthetic cannabinoid nabilone. Addiction 105:3, pages 494-503.
Crossref
Crossref
John J. Coleman, Charles R. Schuster & Robert L. DuPont. (2012) Reducing the Abuse Potential of Controlled Substances. Pharmaceutical Medicine 24:1, pages 21-36.
Crossref
Crossref
Ryan Vandrey & Margaret Haney. (2009) Pharmacotherapy for Cannabis Dependence. CNS Drugs 23:7, pages 543-553.
Crossref
Crossref
Glenn Schwarcz, Basawaraj Karajgi & Richard McCarthy. (2009) Synthetic Δ-9-Tetrahydrocannabinol (Dronabinol) Can Improve the Symptoms of Schizophrenia. Journal of Clinical Psychopharmacology 29:3, pages 255-258.
Crossref
Crossref
Mark Seierstad & J. Guy Breitenbucher. (2008) Discovery and Development of Fatty Acid Amide Hydrolase (FAAH) Inhibitors. Journal of Medicinal Chemistry 51:23, pages 7327-7343.
Crossref
Crossref
Samya Z. Nasr & Donna Drury. (2008) Appetite stimulants use in cystic fibrosis. Pediatric Pulmonology 43:3, pages 209-219.
Crossref
Crossref
Tânia B. e Silva, Mariano A. Pereira, Valéria S. Malta, Edson S. Bento, Miguel A. San‐Miguel, Roberta L. Ziolli, João B. L. Martins, Andre Sih & Carlton A. Taft. (2008) Study of the structure‐activity relationship for theoretical molecular descriptors using density functional theory and chemometric methods in cannabinoid metabolites. International Journal of Quantum Chemistry 108:13, pages 2530-2539.
Crossref
Crossref
Margaret Haney, Erik W Gunderson, Judith Rabkin, Carl L Hart, Suzanne K Vosburg, Sandra D Comer & Richard W Foltin. (2007) Dronabinol and Marijuana in HIV-Positive Marijuana Smokers. JAIDS Journal of Acquired Immune Deficiency Syndromes 45:5, pages 545-554.
Crossref
Crossref
John C.M. Brust. 2007. Aspects neurologiques de l'addiction. Aspects neurologiques de l'addiction
273
314
.
Ethan Russo & Geoffrey W. Guy. (2006) A tale of two cannabinoids: The therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Medical Hypotheses 66:2, pages 234-246.
Crossref
Crossref
Carl L. Hart, Margaret Haney, Suzanne K. Vosburg, Sandra D. Comer & Richard W. Foltin. (2005) Reinforcing effects of oral Δ9-THC in male marijuana smokers in a laboratory choice procedure. Psychopharmacology 181:2, pages 237-243.
Crossref
Crossref
Margaret Haney, Judith Rabkin, Erik Gunderson & Richard W. Foltin. (2005) Dronabinol and marijuana in HIV+ marijuana smokers: acute effects on caloric intake and mood. Psychopharmacology 181:1, pages 170-178.
Crossref
Crossref
&NA;. (2004) Cannabinoids courting attention because of their potential in CNS disorders. Drugs & Therapy Perspectives 20:2, pages 19-22.
Crossref
Crossref
John C.M. Brust. 2004. Neurological Aspects of Substance Abuse. Neurological Aspects of Substance Abuse
225
258
.
Manuel Guzmán. (2003) Cannabinoids: potential anticancer agents. Nature Reviews Cancer 3:10, pages 745-755.
Crossref
Crossref
Robert S. Mansbach, Douglas E. Feltner, Lisa H. Gold & Sidney H. Schnoll. (2003) Incorporating the assessment of abuse liability into the drug discovery and development process. Drug and Alcohol Dependence 70:3, pages S73-S85.
Crossref
Crossref
Ethan B. Russo & John M. McPartland. (2002) Cannabis is more than simply Δ9-tetrahydrocannabinol. Psychopharmacology 165:4, pages 431-432.
Crossref
Crossref
Franjo Grotenhermen. (2003) Pharmacokinetics and Pharmacodynamics of Cannabinoids. Clinical Pharmacokinetics 42:4, pages 327-360.
Crossref
Crossref
n/a n/a. (2002) Dronabinol. pharma-kritik 24:8.
Crossref
Crossref
Elliot M Berry & Raphael Mechoulam. (2002) Tetrahydrocannabinol and endocannabinoids in feeding and appetite. Pharmacology & Therapeutics 95:2, pages 185-190.
Crossref
Crossref